SecBot SecBot

RHHBY drug pipeline

$60.95
+1.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±1.0%
1-day, median of 30 events
IV rank
No data
No current options data
Rated drugs
3
3 neutral
Phase 3 trials
16
0 with results posted

Upcoming catalysts

8 dated
  1. Dec 16, 2026
    Satralizumab
    Phase 3 primary completion
  2. Dec 31, 2026
    Pertuzumab
    Phase 3 primary completion
  3. Dec 31, 2026
    Atezolizumab
    Phase 3 primary completion
  4. Dec 31, 2026
    Afimkibart
    Phase 2 primary completion
  5. Dec 31, 2026
    Atezolizumab
    Phase 2 primary completion
  6. Jan 19, 2027
    Alectinib
    Phase 3 primary completion
  7. Jan 30, 2027
    Afimkibart
    Phase 3 primary completion
  8. Feb 4, 2027
    Lucentis
    Phase 3 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready on the market since 2013.

trastuzumab emtansine ado-trastuzumab emtansine Updated Oct 24

What to watch

The VIVS filing hint is a dead end, VivoSim Labs does not develop trastuzumab emtansine. Investors focused on this drug should watch Roche (RHHBY) for Kadcyla sales trends and competition from Enhertu (AZN/Daiichi), not VIVS. There is no near-term binary catalyst for Kadcyla.

Bull case
  • Kadcyla is an established, approved ADC with over a decade of clinical data supporting its safety and efficacy in HER2-positive breast cancer.
  • The supplemental FDA approval in May 2025 suggests ongoing label expansion efforts by Genentech/Roche.
  • As one of the first ADCs to market, it has strong brand recognition and a well-established reimbursement pathway.
Bear case
  • Kadcyla faces intense competition from Enhertu (trastuzumab deruxtecan, AstraZeneca/Daiichi Sankyo), which has demonstrated superior efficacy in head-to-head trials including DESTINY-Breast03.
  • The April 2026 FDA safety labeling update added boxed warnings for hepatotoxicity, cardiac toxicity, and embryo-fetal toxicity, reflecting serious safety concerns.
  • For Roche, Kadcyla is not a pipeline-driving binary event, it is an already-commercialized product in a large portfolio, limiting any single-product stock impact.
● neutral
Impact
PhasePhase 3
Time to marketIf Phase 3 trials succeed, potential regulatory filing could occur in 2028-2029, with possible FDA approval in 2029-2030 at the earliest.

trontinemab Updated Nov 5

What to watch

The next hard catalyst for trontinemab is the Phase 3 TRONTIER 1/2 topline readout, currently estimated for February 2028, more than 12 months away. Interim biomarker updates may come at medical conferences (e.g., AAIC, CTAD, AD/PD) but these are not binary stock-moving events for a company the size of Roche. For a non-diversified investor, the key question is whether trontinemab's rapid amyloid clearance and low ARIA rate in Phase 1b/2a will translate into a cognitive-slowing benefit in Phase 3, replicating or improving on lecanemab/donanemab's efficacy while offering a better safety profile.

Bull case
  • Phase 1b/2a data showed 91% of patients became amyloid PET negative at 28 weeks at the 3.6 mg/kg dose, with ARIA-E rates below 5%, a significantly better safety profile than approved competitors (Leqembi ARIA-E ~12.5%, Kisunla ARIA-E ~24%).
  • Trontinemab's Brainshuttle technology achieves ~50x greater brain penetration than gantenerumab, clearing plaques in deep brain regions that other antibodies cannot reach, potentially offering superior efficacy.
  • CSF and plasma biomarkers of Alzheimer's pathology (A-beta, p-tau, neurogranin, GFAP) all normalized in the Phase 1b/2a study, suggesting broad disease-modifying activity.
Bear case
  • Phase 3 TRONTIER trials may fail to show a statistically significant cognitive-slowing benefit, as happened with Roche's earlier anti-amyloid antibody gantenerumab (which failed in Phase 3).
  • Amyloid PET clearance does not guarantee clinical efficacy; the correlation between plaque removal and cognitive benefit remains debated.
  • Competition from already-approved anti-amyloid therapies Leqembi (lecanemab, Eisai/Biogen) and Kisunla (donanemab, Eli Lilly) means trontinemab would enter a crowded market if approved, facing access and reimbursement hurdles.
● neutral
Impact
PhaseApproved (marketed)
Time to marketAlready marketed — FDA approval June 30, 2006; on the market for ~20 years.

Lucentis ranibizumab Updated Aug 21

What to watch

Correct the filing hint: Lucentis is a Genentech/Roche drug; Novartis only held ex-US commercialization rights. For a non-medical investor this is not a catalyst stock, watch instead how fast Harrow's interchangeable ranibizumab biosimilar Byooviz (US launch July 1, 2026) and longer-acting rivals like faricimab eat into remaining Lucentis share, visible only in quarterly Roche/Novartis ophthalmic-sales lines.

Bull case
  • Established blockbuster with ~20 years of real-world use and FDA approval dated 2006-06-30; it is still the reference standard, used as the active comparator arm in current Phase 2/3 trials by Roche, EyeBiotech and AbbVie.
  • Roche extended the ranibizumab franchise with the Susvimo port delivery system (ranibizumab implant; EMA EPAR opinion recorded 2026-07-24), keeping some differentiation beyond the monthly-injection product.
  • US biosimilar competition only reached full force recently, Harrow's interchangeable Byooviz was commercially launched in the US on July 1, 2026, meaning the erosion is still playing out rather than already fully priced for the ex-US Novartis share.
Bear case
  • Patents long expired and biosimilars are now commercial: Harrow launched Byooviz (ranibizumab-nuna), an FDA-approved interchangeable biosimilar referencing Lucentis, in the US on July 1, 2026, with supportive data presented at ASRS 2026 on July 20, classic price-erosion setup.
  • Superior dosing competition: newer anti-VEGFs (e.g., Roche's faricimab, and Regeneron's Eylea) offer longer injection intervals, while cheap off-label bevacizumab remains a price anchor, monthly-injection Lucentis loses share.
  • Zero binary upside: no pending FDA decision, pivotal readout or label expansion for Lucentis itself, so the drug can only bleed gradually; it is immaterial to RHHBY's valuation and a declining line inside NVS's ex-US book.

Other drugs in filings and trials

no drug report yet
  • EVRYSDI Last: Approval · Feb 11, 2025
  • ITOVEBI Last: Approval · Oct 10, 2024
  • OCREVUS ZUNOVO Last: Approval · Sep 13, 2024
  • TECENTRIQ HYBREZA Last: Approval · Sep 12, 2024
  • PIASKY Last: Approval · Jun 20, 2024
  • ROZLYTREK Last: Approval · Oct 20, 2023
  • COLUMVI Last: Approval · Jun 15, 2023
  • LUNSUMIO Last: Approval · Dec 22, 2022
  • XOFLUZA Last: Approval · Aug 11, 2022
  • VABYSMO Last: Approval · Jan 28, 2022
  • ENSPRYNG Last: Approval · Aug 14, 2020
  • PHESGO Last: Approval · Jun 29, 2020
  • POLIVY Last: Approval · Jun 10, 2019
  • HERCEPTIN HYLECTA Last: Approval · Feb 28, 2019
  • HEMLIBRA Last: Approval · Nov 16, 2017
  • RITUXAN HYCELA Last: Approval · Jun 22, 2017
  • OCREVUS Last: Approval · Mar 28, 2017
  • TECENTRIQ Last: Approval · Oct 18, 2016
  • ALECENSA Last: Approval · Dec 11, 2015
  • COTELLIC Last: Approval · Nov 10, 2015
  • GAZYVA Last: Approval · Nov 1, 2013
  • ACTEMRA Last: Approval · Oct 21, 2013
  • PERJETA Last: Approval · Jun 8, 2012
  • ERIVEDGE Last: Approval · Jan 30, 2012
  • Afimkibart 2 trials
  • Ascorbic acid 2 trials
  • Atezolizumab 1 trial
  • Crovalimab 1 trial
  • Enicepatide 1 trial
  • Entrectinib 2 trials
  • Giredestrant 1 trial
  • Risdiplam 1 trial
  • Satralizumab 2 trials
  • Trastuzumab 1 trial

Past FDA events & how the stock moved

30 events
DateDrugEvent1 day5 days
Feb 11, 2025EVRYSDIApproval+0.9%+2.0%
Oct 10, 2024ITOVEBIApproval+2.0%+1.8%
Sep 13, 2024OCREVUS ZUNOVOApproval+1.3%+1.9%
Sep 12, 2024TECENTRIQ HYBREZAApproval+4.8%+5.7%
Jun 20, 2024PIASKYApproval+1.7%−0.2%
Oct 20, 2023ROZLYTREKApproval−0.3%−1.0%
Jun 15, 2023COLUMVIApproval+2.4%+0.9%
Dec 22, 2022LUNSUMIOApproval−1.4%−1.9%
Aug 11, 2022XOFLUZAApproval−0.2%−0.3%
Jan 28, 2022VABYSMOApproval+1.9%−2.1%
Oct 22, 2021LucentisApproval−0.7%−1.0%
Aug 14, 2020ENSPRYNGApproval+0.3%+1.6%
Aug 7, 2020EVRYSDIApproval−1.4%−2.0%
Jun 29, 2020PHESGOApproval−1.2%−0.7%
Aug 15, 2019ROZLYTREKApproval+0.6%+0.2%
Jun 10, 2019POLIVYApproval−0.4%+0.6%
Feb 28, 2019HERCEPTIN HYLECTAApproval0.0%−0.6%
Oct 24, 2018XOFLUZAApproval−5.2%−1.4%
Nov 16, 2017HEMLIBRAApproval+1.3%+10.0%
Jun 22, 2017RITUXAN HYCELAApproval+0.5%−2.4%
Mar 28, 2017OCREVUSApproval−0.3%−0.3%
Oct 18, 2016TECENTRIQApproval+0.3%−2.5%
May 18, 2016TECENTRIQApproval−1.0%+3.0%
Dec 11, 2015ALECENSAApproval−1.1%−0.6%
Nov 10, 2015COTELLICApproval−0.8%−0.1%
Nov 1, 2013GAZYVAApproval+0.7%−1.2%
Oct 21, 2013ACTEMRAApproval+2.6%+3.5%
Feb 22, 2013trastuzumab emtansineApproval+1.8%+1.0%
Jun 8, 2012PERJETAApproval−0.8%+2.4%
Jan 30, 2012ERIVEDGEApproval−0.7%−0.6%

Clinical trials

40 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
LucentisA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)Phase 3Active not recruiting451Feb 4, 2027
AfimkibartA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative ColitisPhase 3Active not recruiting400Jan 30, 2027
AlectinibA Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Phase 3Active not recruiting68Jan 19, 2027
PertuzumabA Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical TrialPhase 3Active not recruiting154Dec 31, 2026
AtezolizumabA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)Phase 3Active not recruiting382Dec 31, 2026
AfimkibartAfimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's DiseasePhase 2Active not recruiting21Dec 31, 2026
AtezolizumabA Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial CancerPhase 2Active not recruiting204Dec 31, 2026
SatralizumabA Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisPhase 3Active not recruiting122Dec 16, 2026
RO7204239A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular AtrophyPhase 3Completed97Nov 2, 2026
GlofitamabAn Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaPhase 2Completed211Oct 22, 2026
TobemstomigA Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerPhase 2Completed83Oct 15, 2026
AzacitidineAZA + Venetoclax as Maintenance Therapy in Patients With AML in RemissionPhase 2Terminated36Oct 12, 2026
TobemstomigA Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomaPhase 2Completed199Oct 5, 2026
Ascorbic acidAdjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung CancerPhase 2Terminated3Sep 24, 2026
AtezolizumabA Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder CancerPhase 2Completed32Sep 22, 2026
TrastuzumabPre Operative Trastuzumab in Operable Breast CancerPhase 3Terminated1,100Sep 11, 2026
trastuzumab emtansineTrial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant CancersPhase 2Completed131Sep 4, 2026
LucentisA Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DMEPhase 3Active not recruiting984Sep 2026
SatralizumabA Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)Phase 2Active not recruiting30Aug 26, 2026
GiredestrantA Study of Giredestrant in Participants With Grade 1 Endometrial CancerPhase 2Completed33Aug 25, 2026
LucentisStudy of Zifibancimig in Participants With Neovascular Age-related Macular DegenerationPhase 2Completed177Aug 25, 2026
RO7204239A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related ComorbidityPhase 2Active not recruiting285Aug 24, 2026
Ascorbic Acid 1000 MGVitamin C Effectiveness in Preventing Urinary Tract Infections After Gynecological SurgeriesPhase 2Completed200Aug 15, 2026
CrovalimabStudy to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal HemoglobinuriaPhase 2Completed59Aug 13, 2026
AlectinibA Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)Phase 3Completed11Jul 31, 2026
trastuzumab emtansineHER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast CancerPhase 2Terminated87Jul 23, 2026
TiragolumabA Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyPhase 3Completed760Jul 22, 2026
AtezolizumabA Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabPhase 3Active not recruiting557Jun 30, 2026
EntrectinibStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment OptionsPhase 2Active not recruiting69Jun 30, 2026
AtezolizumabAn Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)Phase 3Active not recruiting49Jun 30, 2026
MosunetuzumabA Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular LymphomaPhase 3Active not recruiting478May 31, 2026
Tominersen 60 mgGENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's DiseasePhase 2Active not recruiting301May 31, 2026
AtezolizumabNeoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial CancerPhase 2Completed32May 30, 2026
EnicepatideA Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusPhase 2Completed447May 29, 2026
AzacitidineVenetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaPhase 2Terminated34May 29, 2026
LucentisA Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic MyopiaPhase 3Completed280May 22, 2026
RO7446603A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular EdemaPhase 2Completed388May 19, 2026
EntrectinibBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)Phase 2Active not recruiting534May 14, 2026
RisdiplamA Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular AtrophyPhase 2Completed11May 4, 2026
XL092Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerPhase 3Active not recruiting901May 2026